This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre Leon Berard, University Claude Bernard - Lyon 1. Active years: 2014.
Company Filing History:
1 out of 39 
1 out of 215 
Years Active: 2014
Title: Julie Vendrell: Innovator in Cancer Prognostics
Introduction
Julie Vendrell is a prominent inventor based in Villeurbanne, France. She has made significant contributions to the field of cancer research, particularly in the development of prognostic biomarkers for breast cancer. Her work focuses on understanding the genetic factors that influence cancer progression and recurrence.
Latest Patents
Julie Vendrell holds a patent for her invention titled "ZNF217: A New Prognostic and Predictive Biomarker of Recurrent Invasive and Metastatic Phenotypes in Breast Cancer." This patent describes methods for determining the prognosis of cancer by assessing the expression levels of the ZNF217 gene in cancer cell samples. Over-expression of ZNF217 is correlated with a higher likelihood of metastasis and cancer relapse, providing valuable insights for treatment strategies.
Career Highlights
Throughout her career, Julie has worked with esteemed institutions such as the Centre Léon Bérard and the University Claude Bernard - Lyon 1. Her research has been pivotal in advancing the understanding of breast cancer and improving patient outcomes through innovative diagnostic methods.
Collaborations
Julie has collaborated with notable colleagues in her field, including Pierre Roux and Pascale Cohen. These partnerships have enhanced her research efforts and contributed to the development of effective cancer prognostic tools.
Conclusion
Julie Vendrell's work exemplifies the impact of innovative research in the medical field. Her contributions to cancer prognostics are vital for improving patient care and treatment outcomes.